Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00268983 | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | completed | Phase 3 | 14 | GlaxoSmithKlineINDUSTRY | 3 | Jan 9, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 |
| clinicaltrials |
| NCT00053053 | Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer | completed | Phase 3 | 472 | Radiation Therapy Oncology GroupNETWORK | 2 | Dec 8, 2016 | clinicaltrials |
| NCT01949805 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera(PROUD-PV) | completed | Phase 3 | 257 | AOP Orphan Pharmaceuticals AGINDUSTRY | 14 | Nov 28, 2016 | clinicaltrials |
| NCT00000589 | Trial to Reduce Alloimmunization to Platelets (TRAP) | completed | Phase 3 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Nov 7, 2016 | clinicaltrials |
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | completed | Phase 3 | 184 | US Oncology ResearchINDUSTRY | 1 | Nov 3, 2016 | clinicaltrials |
| NCT01481909 | Study on Mastocytosis for Rupatadine Treatment(SMART) | completed | Phase 2 / Phase 3 | 30 | Marcus MaurerOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT01237639 | Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation(TRIST) | completed | Phase 3 | 300 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT00750737 | Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | completed | Phase 3 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT00145002 | A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) | completed | Phase 3 | 130 | Japan Clinical Oncology GroupOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00147121 | Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) | completed | Phase 2 / Phase 3 | 300 | Haruhiko FukudaOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00121303 | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 600 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT02736721 | Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) | completed | Phase 3 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00093990 | Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 457 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Sep 14, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT00046683 | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | completed | Phase 3 | 284 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jul 28, 2016 | clinicaltrials |
| NCT00058331 | Epoetin Alfa in Treating Anemia in Patients With Solid Tumors | completed | Phase 3 | 365 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00003600 | Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy | completed | Phase 3 | 344 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
| NCT01034163 | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)(PATH) | completed | Phase 3 | 41 | Novartis PharmaceuticalsINDUSTRY | 14 | Jul 7, 2016 | clinicaltrials |
| NCT00006348 | Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment | completed | Phase 3 | 100 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00327678 | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | completed | Phase 3 | 1,080 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 27, 2016 | clinicaltrials |
| NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | completed | Phase 2 / Phase 3 | 47 | Tampere University HospitalOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00476541 | NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | completed | Phase 3 | 250 | University of AarhusOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00050531 | High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | completed | Phase 3 | 94 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00000591 | T-Cell Depletion in Unrelated Donor Marrow Transplantation | completed | Phase 3 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 15, 2016 | clinicaltrials |
| NCT01324596 | A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib(REMoDL-B) | completed | Phase 3 | 1,132 | University Hospital Southampton NHS Foundation TrustOTHER | 2 | Apr 15, 2016 | clinicaltrials |
| NCT01275196 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | completed | Phase 3 | 267 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01751867 | An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome | completed | Phase 3 | 135 | Xian-Janssen Pharmaceutical Ltd.INDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00495287 | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) | completed | Phase 3 | 573 | Northern Italy Leukemia GroupOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT00123760 | Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer | completed | Phase 2 / Phase 3 | 10,838 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01530594 | Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 440 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01511289 | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | completed | Phase 3 | 242 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 4 | Feb 24, 2016 | clinicaltrials |
| NCT00005945 | Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia | completed | Phase 3 | 3,054 | Children's Oncology GroupNETWORK | 5 | Feb 23, 2016 | clinicaltrials |
| NCT00002766 | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | completed | Phase 3 | 170 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients(XOLMA) | completed | Phase 2 / Phase 3 | 17 | University of ZurichOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01892618 | Pneumococcal Vaccine in Untreated CLL Patients | completed | Phase 3 | 134 | Karolinska University HospitalOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | completed | Phase 3 | 124 | Hoffmann-La RocheINDUSTRY | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | completed | Phase 3 | 668 | University of ArkansasOTHER | 1 | Nov 23, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | completed | Phase 3 | 212 | Gary MorrowOTHER | 3 | Nov 11, 2015 | clinicaltrials |
| NCT01160315 | Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure(Erasme-POF) | completed | Phase 2 / Phase 3 | 118 | Erasme University HospitalOTHER | 3 | Oct 30, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT01621672 | UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | completed | Phase 3 | 42 | University of ArkansasOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00111748 | UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | completed | Phase 3 | 180 | University of ArkansasOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00085709 | S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | completed | Phase 3 | 637 | SWOG Cancer Research NetworkNETWORK | 3 | Sep 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2017source: clinicaltrials